Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"
Executive Summary
Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).
You may also be interested in...
Amgen Ends Praecis Plenaxis Collaboration After FDA Requests More Studies
Praecis is planning additional studies on the prostate cancer treatment Plenaxis (abarelix) to evaluate switching non-responders to alternate therapies.
Amgen Ends Praecis Plenaxis Collaboration After FDA Requests More Studies
Praecis is planning additional studies on the prostate cancer treatment Plenaxis (abarelix) to evaluate switching non-responders to alternate therapies.
Amgen Aranesp European Approval For Dialysis Use Permits Bi-Weekly Dosing
Chronic renal failure patients receiving Amgen's Aranesp "have been treated successfully with doses administered once every two weeks," European product labeling states.